MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss available
to common...
-$124,021K
Interest income
$4,146K
Zembrace Symtouch
$9,314K
Tosymra
$2,372K
Tonmya
$1,421K
Grant income
$3,012K
Operating loss
-$125,703K
Product revenue, net
$13,107K
Other expense, net
-$3,295K
Loss on
extinguishment of debt
-$2,092K
Interest expense
$89K
Total operating
expenses
$138,810K
Selling, general and
administrative
$87,684K
Research and development
$44,486K
Cost of sales
$6,640K
Back
Back
Income Statement
source: myfinsight.com
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)